• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Look for the Rally in Charles River Labs to Continue

Here's how traders can play shares of the contract research company.
By BRUCE KAMICH
Feb 24, 2021 | 10:20 AM EST
Stocks quotes in this article: CRL

For his final "Executive Decision" segment of Mad Money Tuesday, Jim Cramer checked in Jim Foster, chairman, president and CEO of Charles River Labs (CRL) , the contract research company helping the biotech and pharma industries bring better, safer products to market faster.

Foster started off by saying that Charles River worked on 80% of all the drugs that have been approved over the past three years. They provide critical services to help companies discover, test and ultimately get their drugs to market faster than ever before.

Cell and gene therapy is a hot area, Foster noted, and now accounts for 10% of Charles River's revenues.

Biotechs are clearly the engines of growth in the pharmaceutical industry, Foster added. That's how we were able to develop COVID vaccines in record time using messenger RNA technologies.

When we looked at CRL on Feb. 12 of last year, we wrote that, "CRL has been in a strong technical trend for some time now. New highs just confirms the strength. Stay long or go long on a dip towards $173-$172 and risk a close below $165. The $226 area is our price target." We reached the $226 target in September.

Let's check the CRL charts again.

In the updated daily bar chart of CRL, below, we can see an impressive rally from the March low. Prices are trading above the rising 50-day moving average line as well as the rising 200-day moving average line. After a period of sideways movement the On-Balance-Volume (OBV) line has been firming again since December. A rising OBV line tells us that buyers of CRL are being more aggressive.

The Moving Average Convergence Divergence (MACD) oscillator is above the zero line but poised to cross to the downside for a take profits sell signal.

In this weekly bar chart of CRL, below, we can see a long base pattern in the $135 area. Prices are in an uptrend and trading above the rising 40-week moving average line.

The weekly OBV line is constructive and the MACD oscillator is bullish.

In this daily Point and Figure chart of CRL, below, we can see a potential upside price target in the $378 area.

Bottom-line strategy: Traders could go long CRL or add to longs on available weakness. Risk to $240 for now. Our price targets are $300 and then $378.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Health Care Equipment & Services | Science | Technology | Mad Money | Executive Interview

More from Stocks

Fear and Anxiety on Wall Street

James "Rev Shark" DePorre
Aug 17, 2022 4:41 PM EDT

We've got fear of missing out and wariness that the market may keep running away to the upside.

Peabody Is Glowing Hot

Mark Sebastian
Aug 17, 2022 3:19 PM EDT

Here's how to play Peabody Energy as it looks like it could fire up over $25.

It's Hard to Say What's Cookin' at Weber, Though It Smells Like a Short Squeeze

Jonathan Heller
Aug 17, 2022 11:30 AM EDT

The grillmaker's stock has traded wildly and heavily at times, most recently this week after it posted its latest results on Monday.

Dour Day Shows Why I've Been Raising Cash Into Strength

James "Rev Shark" DePorre
Aug 17, 2022 10:44 AM EDT

I'm not aggressively bearish, but just waiting for better technical conditions.

Target Badly Misses the Mark, Which Sets It Up for a Bearish Bet

Stephen Guilfoyle
Aug 17, 2022 10:30 AM EDT

The big retailer's second-quarter results were atrocious and so is its balance sheet, which makes it a stock not to buy right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login